CorMedix Inc

CorMedix, a Nasdaq‑listed biopharma firm, is redefining infectious & inflammatory disease treatment with a robust pipeline and global expansion, offering investors a low‑P/E, growth‑oriented opportunity.

CorMedix Inc. has made a strategic acquisition of Melinta Therapeutics, valued at $300 million, to create a diversified specialty company with a strong presence in acute care settings.